Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 13 of 13

Filter Applied: cost (Click to remove)

Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021

Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage
Stroke 50:529-536, Bower, M.M.,et al, 2019

Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018

Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020

Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013

Continuous and Routine EEG in Intensive Care
Neurol 81:2002-2008, Ney, J.P.,et al, 2013

Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011

Generic Antiepileptic Drugs and Associated Medical Resource Utilization in the United States
Neurol 74:1566-1574, 1562, Labiner,D.M., et al, 2010

The Risks and Costs of Multiple-Generic Substitution of Topiramate
Neurol 72:2122-2129, Duh,M.S.,et al, 2009

Diagnosis and Management of Neuropathic Pain
BMJ 339:391-395, Freynhagen,R. &Bennett,M.I., 2009

The Value of Specifying Brand-Name Antiepileptic Drugs
Arch Neurol 66:1415-1416, 1418, Ng,Y., 2009

Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Arch Neurol 66:1417-1418, Hamiwka,L., 2009



Showing articles 0 to 13 of 13